Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been used to reduce glucose
levels in patients with type 2 diabetes mellitus since 2005. This meta-analysis discusses the …

Atherosclerotic cardiovascular disease (ASCVD), heart failure (HF) and chronic kidney
disease (CKD) are major complications of type 2 diabetes (T2DM). The objectives of …

Abstract Background Sodium–Glucose Cotransporter-2 Inhibitor (SGLT2i) is a novel oral
drug for treating type 2 diabetes mellitus (T2DM) with demonstrated cardiovascular benefits …

Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal
disorders is challenging because of the potential for interference with the absorption of …

The coexistence of heart failure is frequent and associated with higher mortality in patients
with type 2 diabetes (T2DM), and its management is a critical issue. The WATCH-DM risk …

An integral component of the practice of medicine is focused on the initiation of medications,
based on clinical practice guidelines and underlying trial evidence, which usually test the …

The global prevalence of diabetes mellitus (DM) has led to a pandemic, with significant
microvascular and macrovascular complications including coronary artery disease (CAD) …

Epidemiologic, genetic, and clinical intervention studies have indisputably shown that low-
density lipoprotein cholesterol (LDL-C) is causal in the development of atherosclerotic …

Background The pharmacotherapeutic guidelines for type 2 diabetes have changed
considerably during the past decades. SGLT2 inhibitors and GLP-1 receptor agonists have …

Background The impact of glycemic control in the risk of stent failure in subjects with type 2
diabetes (T2D) is currently unknown. Objectives This study sought to study whether poor …